CP
CYTK icon

CenterBook Partners’s Cytokinetics CYTK Stock Holding History

CenterBook Partners’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$661K Sell
7,759
-105
-1% -$7.54K 0.03% 458
2026
Q1 		$518K Buy
+7,864
New +$500K 0.03% 480
2024
Q3 		– Sell
-16,896
Closed -$915K – 472
2024
Q2 		$915K Buy
+16,896
New +$1.02M 0.06% 339

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CenterBook Partners's CYTK Position: Q2 2026 in Review

CenterBook Partners reduced its Cytokinetics (CYTK) stake by 1.3% in Q2 2026, selling an estimated $7.54K and leaving 7,759 shares worth $661K. The position accounts for 0.03% of the portfolio, ranked #458.

CenterBook Partners first reported a position in CYTK in Q2 2024 and has held it in 3 quarters since. The position peaked at $915K in Q2 2024. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • CenterBook Partners held 7,759 shares of Cytokinetics worth $661K as of Q2 2026.
  • CenterBook Partners sold 105 Cytokinetics shares in Q2 2026, an estimated $7.54K.
  • Cytokinetics made up 0.03% of CenterBook Partners's portfolio in Q2 2026, its #458 holding.
  • CenterBook Partners first reported a position in Cytokinetics in Q2 2024 and has held it in 3 quarters since.
  • CenterBook Partners's Cytokinetics position peaked at $915K in Q2 2024.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on CenterBook Partners's 13F filing for Q2 2026, filed 11 Aug 2026.